RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between November 25, 2019 and October 11, 2021. Follow the link below to get more information and be contacted by a member of our team:
https://www.zlk.com/pslra-1/revance-therapeutics-inc-information-request-form?prid=22844&wire=4
RVNC investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) quality control deficiencies existed at the Company's manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Revance during the relevant time frame, you have until February 8, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rvnc-lawsuit-alert-levi--korsinsky-notifies-revance-therapeutics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301474265.html
SOURCE Levi & Korsinsky, LLP
